Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05119920 | Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease | PHASE2 | COMPLETED | 226 | — | — | Jan 3, 2022 | Jul 27, 2022 | Jul 12, 2023 | 19 | United States |
Mean change from baseline in the VAS score at Day 28 visit. Visual Analogue Scale from 0 (no discomfort) to 100 (maximal discomfort)
| Arm | Type | Description |
|---|---|---|
| Pilocarpine Ophthalmic Topical Cream, Dose 1 | EXPERIMENTAL | Pilocarpine Ophthalmic Topical Cream, Dose 1 |
| Pilocarpine Ophthalmic Topical Cream, Dose 2 | EXPERIMENTAL | Pilocarpine Ophthalmic Topical Cream, Dose 2 |
| Pilocarpine Ophthalmic Topical Cream, Dose 3 | EXPERIMENTAL | Pilocarpine Ophthalmic Topical Cream, Dose 3 |
| Placebo Ophthalmic Topical Cream | PLACEBO_COMPARATOR | Placebo Ophthalmic Topical Cream |
| Name | Type | Description |
|---|---|---|
| Pilocarpine Ophthalmic Topical Cream, Dose 1 | DRUG | Pilocarpine Ophthalmic Topical Cream, Dose 1 |
| Pilocarpine Ophthalmic Topical Cream, Dose 2 | DRUG | Pilocarpine Ophthalmic Topical Cream, Dose 2 |
| Pilocarpine Ophthalmic Topical Cream, Dose 3 | DRUG | Pilocarpine Ophthalmic Topical Cream, Dose 3 |
| Placebo Ophthalmic Topical Cream | DRUG | Placebo Ophthalmic Topical Cream |
Inclusion Criteria: * Male or female, 18 years of age or older at the Screening Visit * Willing and able to provide written informed consent on the IRB/IEC-approved informed consent form * Diagnosis of dry eye Exclusion Criteria: * Sensitivity or known allergy to pilocarpine or any of the other e...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | ABBV-444, REFRESH OPTIVE UD, ABBV-319 |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE2 | GRF312 5% |
| Bausch + Lomb Corporation | BLCO | 1 | PHASE2 | Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Perfluorohexyloctane, Vehicle |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | VSJ-110 |
| Oculis Holding AG | OCS | 1 | PHASE2 | licaminlimab |
| Alcon AG | ALC | 2 | NA | Undisclosed |
| Harrow, Inc. | HROW | 1 | — | Undisclosed |